JP Morgan Lifts ORIC Target as Shorts Quietly Retreat

Short positioning is elevated but quietly easing. At 16.1% of free float, short interest remains firmly in the high camp for a small-cap biotech, but it has declined roughly 8% over the past month from a peak near 18.3 million shares in mid-September. The week-on-week reading ticked up 3.2% on October 13 alone, so the retreat is not linear, but the trend over 30 days points to shorts reducing exposure rather than adding. Borrow conditions do not suggest any near-term squeeze pressure: availability is running at roughly 601% of short interest, meaning shares available to borrow vastly exceed the current short position, and cost to borrow is only 0.47%, low enough that maintaining a short costs virtually nothing. The ORTEX short score of 64.3 has drifted down from a peak of 68 in late September, consistent with the gradual unwind in the short book.

Options positioning has shifted more defensive than usual, worth noting given how call-dominated this name typically is. The put/call ratio reached 0.271 on Tuesday, nearly two standard deviations above its 20-day mean of 0.165. That is still a far cry from the 52-week high of 1.13, but the move is sharp: for most of September and into early October the PCR sat in the 0.11 to 0.20 range before jumping this week. With earnings 30 days out, some demand for downside protection is not unusual for a clinical-stage name, but the size of the shift relative to recent norms suggests the options market is pricing in more uncertainty than it was even a week ago.

One activist holder worth flagging is SR One Capital Management, which filed a Schedule 13D on ORIC in June 2025 and updated it in August. The most recent filing showed its stake at 4.75% of the class, down from 5.4% previously. A 13D filing signals activist intent, though in this context SR One's presence looks more like engaged specialist-biotech capital than a board-seat campaign. As required by disclosure rules, the stake figure is as last reported and holders dropping below 5% may not file again. Alongside SR One, several large institutional managers added meaningfully in the most recent quarter: T. Rowe Price grew its position by 1.2 million shares to 6.4% of the company, BlackRock added 840,000 shares, and State Street put on 1.2 million, all as of September 30. Those three names together represent a notable cluster of long-only buying into a period when the stock was under price pressure.

Insider activity over the past 90 days runs modestly net negative at roughly minus 111,000 shares and minus $1.5 million in value, but the trades are all under 10b5-1 pre-arranged plans, reducing their interpretive weight considerably. CFO Dominic Piscitelli's recent activity reflects the mechanics of option exercise and immediate sale rather than discretionary conviction.

The historical earnings pattern is striking and worth watching into November 13. The two most recent results events each produced next-day gains above 20%, with the August 2026 release delivering a 22% one-day move and extending to roughly 29% over five days. The two prior prints before that were more mixed, a 3.5% gain and a 4% loss. The stock has form for large moves around catalysts, and with 16% of the float short and a 30-day earnings date approaching, the question heading into the print is whether the accumulating institutional sponsorship and converging analyst targets are sufficient to sustain the stock at current levels while the clinical data does the work.